Targeting Resistance to Targeted Therapies: Combating a Resilient Foe.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30352903.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3178 and PMC identifier 6295273.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.<i>See related article by Le et al., p. 6195</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors